Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Cash from Investing Activities (2022)

Historic Cash from Investing Activities for BioXcel Therapeutics (BTAI) over the last 1 years, with Q2 2022 value amounting to -$19000.0.

  • BioXcel Therapeutics' Cash from Investing Activities changed N/A to -$19000.0 in Q2 2022 from the same period last year, while for Sep 2023 it was -$19000.0, marking a year-over-year change of. This contributed to the annual value of -$20000.0 for FY2023, which is 8561.15% up from last year.
  • As of Q2 2022, BioXcel Therapeutics' Cash from Investing Activities stood at -$19000.0.
  • In the past 5 years, BioXcel Therapeutics' Cash from Investing Activities registered a high of -$19000.0 during Q2 2022, and its lowest value of -$120000.0 during Q1 2022.